pharmaphorum Top Stories 23rd September 2024

In last week’s news, we learned that Elon Musk’s Neuralink has inched considerably closer to becoming a reality, with the FDA awarding the implantable brain chip breakthrough status.

Meanwhile, Daiichi Sankyo ’s Vanflyta was recommended for NHS use by NICE as a treatment for a specific form of acute myeloid leukaemia (AML) in England and Wales, and in the US digital health company Noom launched a cut-price pharmacy-made version of 诺和诺德 ’s obesity drug semaglutide to increase accessibility.

And from ESMO, ?news rolled into the early part of the week that 阿斯利康 ’s data for Imfinzi in muscle-invasive bladder cancer (MIBC) held high hopes for FDA approval, though not all agreed, while Incyte’s PD-1 inhibitor Zynyz had new positive data that could see it try again for FDA approval in squamous cell carcinoma of the anal canal (SCAC).

Catch up below and at pharmaphorum.com!

Top Stories

Neuralink gets breakthrough tag for sight-restoring implant

Elon Musk's Neuralink has been awarded breakthrough status from the FDA for an implantable chip – dubbed Blindsight – that promises to restore the sight of people with vision impairment. READ MORE

Daiichi Sankyo's Vanflyta gets NICE nod for leukaemia

Daiichi Sankyo's FLT3 inhibitor Vanflyta has been recommended for NHS use as a treatment for a specific form of acute myeloid leukaemia (AML) in England and Wales, the first countries in Europe to authorise use of the drug. READ MORE

Noom offers cut-price compounded GLP-1 drug for obesity

Digital health company Noom has launched a compound pharmacy-made version of Novo Nordisk's obesity drug semaglutide to make the drug more accessible to consumers in the US. READ MORE

ESMO: NIAGARA backs Imfinzi in bladder cancer, but will FDA?

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that. READ MORE

ESMO: Incyte's PD-1 treads new ground in anal cancer

Incyte's first attempt to get FDA approval for its PD-1 inhibitor Zynyz for squamous cell carcinoma of the anal canal (SCAC) was knocked back by the FDA, but new data could get the programme back on track. READ MORE

Shifting the paradigm in pharma marketing with content transformation

Join us on 25th September at 12pm EST, 5pm BST for an engaging and informative discussion, brought to you by EVERSANA INTOUCH , with a noted customer experience and digital transformation expert, who will discuss learnings from her pharmaceutical industry experience at Takeda and Biogen. In this 30-minutes webinar, participants will learn more about this industry transformation and how to position themselves on the inside track as pharma marketing evolves. REGISTER NOW

Beyond clinical: Boosting recruitment and retention with SDOH data

Join pharmaphorum on Wednesday, 2nd October (1:00pm ET / 10:00am PT / 6:00pm BST) for a webinar, developed in association with Socially Determined , to discover how industry leaders are harnessing non-clinical data to enhance recruitment, retention, and broader evidence generation. REGISTER NOW